Business Description
BioLine Rx Ltd
ISIN : IL0011015182
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 2.24 | |||||
Debt-to-EBITDA | -1.25 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.62 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.5 | |||||
3-Year EPS without NRI Growth Rate | 25.1 | |||||
3-Year FCF Growth Rate | 36.3 | |||||
3-Year Book Growth Rate | -42.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 18.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 85.26 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.12 | |||||
9-Day RSI | 44.01 | |||||
14-Day RSI | 45 | |||||
6-1 Month Momentum % | -33.57 | |||||
12-1 Month Momentum % | -60.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.61 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 1.31 | |||||
Days Inventory | 381.28 | |||||
Days Sales Outstanding | 45.45 | |||||
Days Payable | 1258.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46 | |||||
Shareholder Yield % | -8.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.2 | |||||
Operating Margin % | -204.22 | |||||
Net Margin % | -176.67 | |||||
FCF Margin % | -178.62 | |||||
ROE % | -202.27 | |||||
ROA % | -51.59 | |||||
ROIC % | -106.85 | |||||
3-Year ROIIC % | -345.28 | |||||
ROC (Joel Greenblatt) % | -1409.65 | |||||
ROCE % | -79.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.88 | |||||
PB Ratio | 3.8 | |||||
EV-to-EBIT | -1.63 | |||||
EV-to-Forward-EBIT | -1.38 | |||||
EV-to-EBITDA | -1.78 | |||||
EV-to-Forward-EBITDA | -1.38 | |||||
EV-to-Revenue | 2.6 | |||||
EV-to-Forward-Revenue | 1.88 | |||||
EV-to-FCF | -1.46 | |||||
Earnings Yield (Greenblatt) % | -61.35 | |||||
FCF Yield % | -57.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioLine Rx Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₪) | 64.429 | ||
EPS (TTM) (₪) | -0.114 | ||
Beta | 0 | ||
Volatility % | 67.54 | ||
14-Day RSI | 45 | ||
14-Day ATR (₪) | 0.007509 | ||
20-Day SMA (₪) | 0.1723 | ||
12-1 Month Momentum % | -60.66 | ||
52-Week Range (₪) | 0.147 - 0.567 | ||
Shares Outstanding (Mil) | 1,199.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioLine Rx Ltd Stock Events
Event | Date | Price(₪) | ||
---|---|---|---|---|
No Event Data |
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(XTAE:BLRX)'s stock price today?
When is next earnings date of BioLine Rx Ltd(XTAE:BLRX)?
Does BioLine Rx Ltd(XTAE:BLRX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |